APA (7th ed.) Citation

Lickliter, J., Kanceva, R., Vincent, E., Schueler, A., Harrison-Moench, E., Yue, C. S., . . . Griffin, P. (2020). Pharmacokinetics and Pharmacodynamics of a Proposed Pegfilgrastim Biosimilar MSB11455 Versus the Reference Pegfilgrastim Neulasta in Healthy Subjects: A Randomized, Double-blind Trial. Clinical therapeutics, 42(8), 1508-1518.e1. https://doi.org/10.1016/j.clinthera.2020.05.020

Chicago Style (17th ed.) Citation

Lickliter, Jason, et al. "Pharmacokinetics and Pharmacodynamics of a Proposed Pegfilgrastim Biosimilar MSB11455 Versus the Reference Pegfilgrastim Neulasta in Healthy Subjects: A Randomized, Double-blind Trial." Clinical Therapeutics 42, no. 8 (2020): 1508-1518.e1. https://doi.org/10.1016/j.clinthera.2020.05.020.

MLA (9th ed.) Citation

Lickliter, Jason, et al. "Pharmacokinetics and Pharmacodynamics of a Proposed Pegfilgrastim Biosimilar MSB11455 Versus the Reference Pegfilgrastim Neulasta in Healthy Subjects: A Randomized, Double-blind Trial." Clinical Therapeutics, vol. 42, no. 8, 2020, pp. 1508-1518.e1, https://doi.org/10.1016/j.clinthera.2020.05.020.